FDA
EMA
MHRA
PMDA
Health Canada

Phase I
Phase II
Phase III
Readouts
Enrollment Signals

Pipeline Tracking
Company Moves
Asset Intelligence
Landscape Reports

Markets

Pricing
Access
Commercial
Launch Tracking

M&A Watch

Licensing
Acquisitions
Partnerships
Capital Raises

Strategy Catalysts Pricing

Humanexa Signals

Data-driven pharmaceutical intelligence for biotech investors, pharma operators, consultants, and intelligence teams.

Company

Pricing
Partner with us
Subscribe
Contact
Privacy

Subscribe to Humanexa Signals

Weekly intelligence for pharma decision-makers.

No paywall. No spam. Unsubscribe anytime.

Intelligence powered by the Humanexa engine.

Asset / Drug

Ticagrelor

Drug and asset intelligence for Ticagrelor with 2 indexed intelligence signals across regulatory, clinical, competitive, and market developments.

Signals: 2
Catalysts: 0
Stage: Development stage unavailable

Sponsor company

Micro Labs →

Mechanism of action

Antiplatelet Therapy

Recent signals(2)

ClinicalAugust 16, 2026

Trial on Ticagrelor Monotherapy vs. Ticagrelor plus Aspirin in STEMI Patients

The clinical trial, sponsored by Radboud University Medical Center, is evaluating the safety of ticagrelor monotherapy versus the standard regimen of ticagrelor plus aspirin in patients with ST-elevation myocardial infarction (STEMI) following primary percutaneous coronary intervention (PCI).

RegulatoryJuly 30, 2026

FDA Approves Ticagrelor Application ANDA208539 by Micro Labs

The FDA has approved the original application for Ticagrelor (ANDA208539) submitted by Micro Labs.

Upcoming milestones

No catalysts indexed for this entity yet.

Related catalysts

No catalysts indexed for this entity yet.

Indications

No related entities indexed yet.

Therapeutic areas

Antiplatelet →

Antiplatelet Therapy →

Cardiology →

Newsletter

Get signals before the market moves

Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.

No paywall. No spam. Unsubscribe anytime.